Viyash Scientific (VIYASH) Fundamentals 2026 — P/E 79.0x, Revenue Analysis | SniperIQ
Viyash Scientific (VIYASH) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹11,206 Crore, trading at ₹256.75 on the NSE. This SniperIQ fundamentals page covers Viyash Scientific's valuation (P/E 79.0x, P/B 3.8x), profitability (net margin 4.5%), revenue (₹3,420 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Viyash Scientific's market cap?
Viyash Scientific (VIYASH) has a market capitalization of approximately ₹11,206 Crore, trading at ₹256.75 on the NSE. Market cap moves with the live share price.
What is Viyash Scientific's P/E ratio?
Viyash Scientific's trailing twelve-month P/E ratio is 79.0x, with a price-to-book (P/B) of 3.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Viyash Scientific?
Viyash Scientific runs a net profit margin of 4.5%, a gross margin of 37.3%, and an operating margin of 12.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Viyash Scientific generate?
Viyash Scientific reported revenue of ₹3,420 Crore for fiscal year 2026, with net income of ₹177 Crore and earnings per share (EPS) of 4.09. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Viyash Scientific pay a dividend?
Viyash Scientific does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Viyash Scientific financially healthy?
Viyash Scientific carries a debt-to-equity ratio of 0.17x and a current ratio of 2.38x, with a market beta of 0.93. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Viyash Scientific a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Viyash Scientific (VIYASH) the key facts are: market cap ₹11,206 Crore, P/E 79.0x, revenue ₹3,420 Crore, 52-week range 166-298. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Viyash Scientific's full fundamentals live
Get Viyash Scientific's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.